Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.

NCT00530764 is registered in ClinicalTrials.gov with GW Pharmaceuticals Ltd as lead sponsor.

NCT NCT00530764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00530764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.
Lead sponsor
GW Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
January 31, 2010
Enrollment
360 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pain, palliative care